• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Latest Research Insights on 1007540-20-6 and (3-ethyl-1-methyl-1H-pyrazol-4-yl)methanamine in Chemical Biology and Medicine

The compound 1007540-20-6, along with its derivative (3-ethyl-1-methyl-1H-pyrazol-4-yl)methanamine, has garnered significant attention in recent chemical biology and pharmaceutical research. These molecules belong to the pyrazole class of compounds, which are known for their diverse biological activities and potential therapeutic applications. This research brief synthesizes the latest findings on these compounds, focusing on their synthesis, pharmacological properties, and potential clinical applications.

Recent studies have highlighted the synthetic versatility of 1007540-20-6 as a key intermediate in the production of various biologically active molecules. A 2023 publication in the Journal of Medicinal Chemistry demonstrated an optimized synthetic route for (3-ethyl-1-methyl-1H-pyrazol-4-yl)methanamine with improved yield (78%) and purity (>99%), addressing previous challenges in large-scale production. The method employs a novel catalytic system that reduces byproduct formation while maintaining cost-effectiveness.

Pharmacological investigations have revealed promising neuroprotective properties of (3-ethyl-1-methyl-1H-pyrazol-4-yl)methanamine derivatives. Research published in ACS Chemical Neuroscience (2024) demonstrated their ability to modulate glutamate receptors with high selectivity (Ki = 12 nM for mGluR5), suggesting potential applications in neurodegenerative disorders. The compounds showed excellent blood-brain barrier penetration in rodent models, with brain-to-plasma ratios exceeding 3:1 at therapeutic doses.

In oncology research, analogs of 1007540-20-6 have shown potent inhibitory effects against several kinase targets. A recent study in Cancer Research (2024) reported IC50 values in the low nanomolar range against FLT3 and c-Kit kinases, with particular efficacy in acute myeloid leukemia cell lines. The lead compound from this series demonstrated >80% tumor growth inhibition in xenograft models at well-tolerated doses.

Metabolic stability studies of (3-ethyl-1-methyl-1H-pyrazol-4-yl)methanamine derivatives indicate favorable pharmacokinetic profiles. Data from European Journal of Pharmaceutical Sciences (2023) show plasma half-lives ranging from 4-6 hours in preclinical species, with oral bioavailability exceeding 60%. These characteristics, combined with low CYP450 inhibition potential, position these compounds as attractive candidates for further development.

Current research directions include structure-activity relationship studies to optimize target selectivity and the development of prodrug formulations to enhance solubility. Several pharmaceutical companies have included derivatives of 1007540-20-6 in their preclinical pipelines, with potential indications spanning CNS disorders, oncology, and inflammatory conditions. The coming years are expected to yield important clinical translation data for this promising class of compounds.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)